Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Slow-Growth' Global Trend Shakes Up P&G Product Strategy Start To Finish

Executive Summary

P&G’s health care segment advanced 4% in the third quarter to $1.84bn, but sales declined for its other business units, a trend the firm sees worldwide across consumer industries. CFO Jon Moeller unveils the firm’s “irresistible superiority” product development strategy to counter slower global consumer spending.


Related Content

P&G Open To M&A Moves, Closed To Board Seat For Activist Investor
Tylenol Delivers J&J Relief As Global 'Consumer Staples' Sales Slump
P&G Portfolio Rationalization Brushes Off 20% Of Oral Care SKUs
Manufacturing, Advertising Coalition Tackles Digital Ad-Block Devastation
P&G Crest Whitestrips Patents Stand Up To ‘Indefiniteness’ Challenge
P&G To Cut Portfolio In Half, Refocus On Core In Simplification Strategy


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts